Entelexo Overview
- Year Founded
-
2020
- Status
-
Private
- Employees
-
4
- Latest Deal Type
-
Early Stage VC
- Latest Deal Amount
-
$50K
- Investors
-
5
Entelexo General Information
Description
Developer of modern treatments designed to assist immune-mediated diseases. The company specializes in creating a new class of drugs which include extracellular vesicles that are derived from stem cells, enabling healthcare workers to treat autoimmune diseases.
Contact Information
Website
www.entelexo.comCorporate Office
- 5270 California Avenue
- Suite 300
- Irvine, CA 92617
- United States
Corporate Office
- 5270 California Avenue
- Suite 300
- Irvine, CA 92617
- United States
Entelexo Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 7. Early Stage VC | 23-May-2023 | $50K | Completed | Pre-Clinical Trials | ||
| 6. Accelerator/Incubator | 15-Oct-2021 | Completed | Pre-Clinical Trials | |||
| 5. Equity Crowdfunding | 01-Jul-2021 | Completed | Pre-Clinical Trials | |||
| 4. Seed Round | 28-May-2021 | Completed | Pre-Clinical Trials | |||
| 3. Accelerator/Incubator | 06-Mar-2021 | Completed | Pre-Clinical Trials | |||
| 2. Angel (individual) | 01-Oct-2020 | $278K | $428K | Completed | Startup | |
| 1. Angel (individual) | 01-Jun-2020 | $150K | $150K | Completed | Startup |
VC Exit Predictor
See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.
Entelexo Patents
Entelexo Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| WO-2023250440-A1 | Engineered extracellular vesicles for therapeutic delivery | Inactive | 22-Jun-2022 | ||
| WO-2023076418-A2 | Platforms, compositions, and methods for therapeutic delivery | Inactive | 26-Oct-2021 | ||
| WO-2023076418-A3 | Platforms, compositions, and methods for therapeutic delivery | Inactive | 26-Oct-2021 | ||
| WO-2022133301-A1 | Platforms, compositions, and methods for therapeutic delivery | Inactive | 18-Dec-2020 | ||
| AU-2020298314-A1 | Platforms, compositions, and methods for therapeutics delivery | Inactive | 21-Jun-2019 | C07K14/70521 |
Entelexo Signals
Entelexo Investors (5)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| Endless Frontier Labs | Accelerator/Incubator | Minority | ||
| Acequia Capital | Venture Capital | Minority | ||
| Founders, Inc | Venture Capital | Minority | ||
| Metaplanet Holdings | Venture Capital | Minority | ||
| Y Combinator | Accelerator/Incubator | Minority |
Entelexo FAQs
-
When was Entelexo founded?
Entelexo was founded in 2020.
-
Where is Entelexo headquartered?
Entelexo is headquartered in Irvine, CA.
-
What is the size of Entelexo?
Entelexo has 4 total employees.
-
What industry is Entelexo in?
Entelexo’s primary industry is Drug Discovery.
-
Is Entelexo a private or public company?
Entelexo is a Private company.
-
What is Entelexo’s current revenue?
The current revenue for Entelexo is .
-
How much funding has Entelexo raised over time?
Entelexo has raised $2.64M.
-
Who are Entelexo’s investors?
Endless Frontier Labs, Acequia Capital, Founders, Inc, Metaplanet Holdings, and Y Combinator have invested in Entelexo.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process